PURPOSE The mechanism of cancer cachexia remains unclear and inflammatory cytokines may play a role in its development. Interleukin-6 (IL-6), C-reactive protein (CRP) and tumor necrosis factor-α (TNFα) are known to be associated with cancer cachexia. Tartrate-resistant acid phosphatase 5a (TRACP5a) is proposed to be related to chronic inflammation. In this study we hypothesize that TRACP5a is a...

Cachexia is a complex syndrome that combines weight loss, lipolysis, loss of muscle and visceral protein, anorexia, chronic nausea, and weakness. Severe cachexia occurs in most patients with advanced cancer or AIDS. This article covers approaches to cachexia other than treatment of the underlying disease. In those patients who are eligible for tumouricidal treatment, cachexia may resolve as the...

PURPOSE/OBJECTIVES To explore healthcare professionals' experience, understanding, and perception of the needs of patients with cachexia in advanced cancer. RESEARCH APPROACH A qualitative approach based on symbolic interactionism. SETTING A regional cancer center in a large teaching hospital in the United Kingdom. PARTICIPANTS 34 healthcare professionals who had experience providing care...

Cancer cachexia, the unintentional loss of lean body mass, is associated with decreased quality of life and poor patient survival. Hypogonadism, involving a reduction in circulating testosterone, is associated with the cachectic condition. At this time there is a very limited understanding of the role of hypogonadism in cancer cachexia progression. This gap in our knowledge is related to a lack...

Loss of fat mass is a key feature of cancer cachexia and has been attributed to increased adipocyte lipolysis. The mechanism behind this alteration is unknown and was presently investigated. We studied mature s.c. fat cells and differentiated preadipocytes from 26 cancer patients with and without cachexia. Hormone-induced lipolysis and expression of lipolysis-regulating genes were determined to...

The purpose of this study was to determine the predictive value of IL-6-572, -190, and -634 gene polymorphisms on the cachexia susceptibility and survival time of patients with pancreatic cancer. Genotypes were determined using restriction fragment length polymorphism analysis of polymerase chain reaction products. All of the subjects were homozygous to the C allele of IL-6-190. No significant ...

Approximately 50% of all cancer patients develop cachexia, a paraneoplastic syndrome that is characterized by wasting of adipose tissue and skeletal muscle mass. Cytokines, including TNF-alpha, interleukins-1, -6, and interferon-A are known mediators of the cachectic process. The latter however represent only one of many imbalanced systems in cancer cachexia. The aim of this study was to furthe...

Anorexia-cachexia syndrome develops during the advanced stages of various chronic diseases in which patients exhibit a decreased food intake, weight loss, and muscle tissue wasting. For these patients, this syndrome is a critical problem leading to an increased rate of morbidity and mortality. The present pharmacological therapies for treating anorexia-cachexia have limited effectiveness. The J...

Current research emphasizes the contribution of gut microbiome to numerous health conditions includingcancer and skeletomuscular disorders. Cachexia is a debilitating condition progressive loss bodytissues. It occurs in up 80% patients with tumors, it impairs their functioning quality life andincreases morbidity premature death. Several randomized trials indicate that interventions, which targe...